The use of C5a blockers, the plasma kallikrein and blood coagulation factor XIa (FXIa) inhibitors, and agents neutralizing extracellular histones may be beneficial for the control of COVID-19-induced immunothrombotic dysregulation. This evidence concerns the gene KLK4 and COVID-19.